Sanofi has won FDA clearance for Infilbray (venglustat), positioning the oral therapy as the first US option specifically indicated for neurological symptoms of Gaucher disease. The approval extends Sanofi’s rare-disease portfolio and adds an additional revenue stream as the company prepares for future competitive pressure in broader immunology franchises. The decision caps a prolonged development path for venglustat and underscores continued investor and commercial focus on central nervous system-penetrant formulations for lysosomal storage disorders. For manufacturers, it also reinforces the growing regulatory emphasis on neurologic endpoints and differentiated symptom profiles in ultra-rare indications. The label’s practical impact will depend on confirmatory uptake and payer coverage, but the approval establishes a new treatment category for clinicians managing Gaucher patients with CNS involvement. It also signals ongoing appetite for first-in-class mechanisms that can cross the blood-brain barrier. (Story context: the approval is covered separately from Sanofi’s broader pipeline announcements.)